Pharmacokinetics, mass balance, and tissue distribution of a novel DNA alkylating agent, VNP40101M, in rats
Journal Title: The AAPS Journal - Year 2002, Vol 4, Issue 4
Abstract
VNP40101M (1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(2 methylamino)carbonyl] hydrazine), a novel DNA alkylating agent, is currently under clinical development for the treatment of cancer in Phase I clinical trials. This study investigated the pharmacokinetics, mass balance, and tissue distribution of [14C]-VNP40101M in rats following a single intravenous dose of 10 mg/kg. After 7 days, the total recovery of radioactivity was 85% for males and 79% for females. Most of the radioactivity was eliminated within 48 hours through urine (70%), with less excreted in feces (6%). Tissue contained relatively high radioactive residues with the highest concentrations in kidneys, liver, lung, and spleen. After 7 days, tissue still contained 9% of the dose. At both 5 minutes and 1 hour post-dose, brain contained relatively high radioactivity (5.9 and 3.3 μg equivalence/g and 50% and 30% of the blood concentration, respectively), suggesting that VNP40101M penetrated the blood-brain barrier. The elimination half-life of VNP40101M was approximately 20 minutes, the peak plasma concentration (Cmax) averaged 11.3 μg/mL, the volume of distribution (Vss) averaged 0.91 L/kg, and the total body clearance (CI) averaged 33.5 mL/min/kg. The metabolite profile in urine was complex, indicating VNP40101M was extensively metabolized. There were no apparent sex differences in pharmacokinetic parameters of VNP40101M in the rat.
Authors and Affiliations
John Mao, Yang Xu, Diana Wu, Bijan Almassain
Keywords
Related Articles
- EP ID EP682018
- DOI 10.1208/ps040424
- Views 116
- Downloads 0
Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models
The online version of this article (doi:10.1208/s12248-011-9255-z) contains supplementary material, which is available to authorized users.
Role of morphine's metabolites in analgesia: Concepts and controversies
The metabolites of morphine, morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G), have been extensively studied for their contribution to clinical effects following administration of morphine. Those contributio...
Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development
While narcotic analgesics such as morphine, which act preferentially through mu opioid receptors, remain the gold standard in the treatment of severe pain, their use is limited by detrimental liabilities such as respirat...
Strategic Biomarkers for Drug Development in Treating Rare Diseases and Diseases in Neonates and Infants
There are similar challenges in developing a product designed to treat patients with a rare disease and drugs to treat critically ill neonates and infants. Part of the challenge in developing such products as well as ide...
Exposure-response relationships and drug interactions of sirolimus
Sirolimus (rapamycin, RAPAMUNE, RAPA) is an immunosuppressive agent used for the prophylaxis of renal allograft rejection and exhibits an immunosuppressive mechanism that is distinct from that for cyclosporine and tacrol...